These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 15077313)

  • 1. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.
    Foell D; Wittkowski H; Hammerschmidt I; Wulffraat N; Schmeling H; Frosch M; Horneff G; Kuis W; Sorg C; Roth J
    Arthritis Rheum; 2004 Apr; 50(4):1286-95. PubMed ID: 15077313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis.
    Wittkowski H; Foell D; af Klint E; De Rycke L; De Keyser F; Frosch M; Ulfgren AK; Roth J
    Ann Rheum Dis; 2007 Aug; 66(8):1020-5. PubMed ID: 17223658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.
    Frosch M; Strey A; Vogl T; Wulffraat NM; Kuis W; Sunderkötter C; Harms E; Sorg C; Roth J
    Arthritis Rheum; 2000 Mar; 43(3):628-37. PubMed ID: 10728757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
    Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
    J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A; Viswanath V; Singh YP; Aggarwal A
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis.
    Madson KL; Moore TL; Lawrence JM; Osborn TG
    J Rheumatol; 1994 Dec; 21(12):2359-63. PubMed ID: 7699643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes.
    De Benedetti F; Pignatti P; Bernasconi S; Gerloni V; Matsushima K; Caporali R; Montecucco CM; Sozzani S; Fantini F; Martini A
    J Rheumatol; 1999 Feb; 26(2):425-31. PubMed ID: 9972980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
    Kimura Y; Pinho P; Walco G; Higgins G; Hummell D; Szer I; Henrickson M; Watcher S; Reiff A
    J Rheumatol; 2005 May; 32(5):935-42. PubMed ID: 15868633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept therapy in children with juvenile rheumatoid arthritis.
    Hung JJ; Huang JL
    J Microbiol Immunol Infect; 2005 Dec; 38(6):444-6. PubMed ID: 16341346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis.
    Foell D; Kane D; Bresnihan B; Vogl T; Nacken W; Sorg C; Fitzgerald O; Roth J
    Rheumatology (Oxford); 2003 Nov; 42(11):1383-9. PubMed ID: 12832707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.
    Takei S; Groh D; Bernstein B; Shaham B; Gallagher K; Reiff A
    J Rheumatol; 2001 Jul; 28(7):1677-80. PubMed ID: 11469478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
    Lovell DJ; Giannini EH; Reiff A; Jones OY; Schneider R; Olson JC; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Lange M; Finck BK; Burge DJ;
    Arthritis Rheum; 2003 Jan; 48(1):218-26. PubMed ID: 12528122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.
    Ramanan AV; Schneider R
    J Rheumatol; 2003 Feb; 30(2):401-3. PubMed ID: 12563702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.
    Liang TC; Yang YH; Lin YT; Chiang BL
    J Microbiol Immunol Infect; 2005 Dec; 38(6):447-50. PubMed ID: 16341347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.